MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

Cardio Diagnostics Holdings, Inc. (CDIO)

Cardio Diagnostics Holdings, Inc. (CDIO)

|||

Cash Flow Overview

Change in Cash
-$1,490,324
Free Cash flow
-$1,342,364
Unit: Dollar
Positive Cash Flow Breakdown
    • Prepaid expenses and other curre...
    • Amortization
    • Depreciation
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Payments of finance agreement
    • Lease liability
    • Patent costs incurred
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-1,501,468
-1,788,158
-1,465,368
-1,714,536
Depreciation
44,283
44,240
44,220
40,402
Amortization
51,158
50,412
49,857
49,186
Stock-based compensation expense
24,352
24,733
24,083
24,762
Accounts receivable
-369
-3,852
-3,095
-1,706
Prepaid expenses and other current assets
-93,963
-138,627
-96,324
-162,888
Accounts payable and accrued expenses
7,112
25,528
-53,292
102,010
Lease liability
-62,133
-61,446
-60,768
-59,836
Net cash used in operating activities
-1,342,364
-1,562,212
-1,361,849
-1,393,418
Purchases of property and equipment
0
1,760
0
162,834
Patent costs incurred
46,789
61,936
78,359
94,985
Net cash used in investing activities
-46,789
-63,696
-78,359
-257,819
Proceeds from sale of common stock, net of issuance costs
0
3,693,470
263,068
116,646
Payments of finance agreement
101,171
101,171
67,448
76,691
Net cash provided by financing activities
-101,171
3,592,299
195,620
39,955
Net increase in cash
-1,490,324
1,966,391
-1,244,588
-1,611,282
Cash - beginning of period
7,077,021
5,110,630
6,355,218
7,827,487
Cash - end of period
5,586,697
7,077,021
5,110,630
6,355,218
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Net increase in cash-$1,490,324 (-1172.08%↓ Y/Y)Prepaid expenses andother current assets-$93,963 (57.44%↑ Y/Y)Amortization$51,158 (-63.20%↓ Y/Y)Depreciation$44,283 (-41.30%↓ Y/Y)Stock-based compensationexpense$24,352 (-60.33%↓ Y/Y)Accounts payable andaccrued expenses$7,112 (118.27%↑ Y/Y)Accounts receivable-$369 (93.51%↑ Y/Y)Net cash used inoperating activities-$1,342,364 (54.83%↑ Y/Y)Net cash provided byfinancing activities-$101,171 (-103.17%↓ Y/Y)Net cash used ininvesting activities-$46,789 (43.72%↑ Y/Y)Canceled cashflow$221,237 Net loss-$1,501,468 (54.75%↑ Y/Y)Payments of financeagreement$101,171 (-56.03%↓ Y/Y)Patent costs incurred$46,789 (-20.22%↓ Y/Y)Lease liability-$62,133 (46.74%↑ Y/Y)